A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

A randomized trial compared short-term androgen deprivation with high-dose radiotherapy (STADT-RT) and high-dose radiation therapy alone in localized prostate cancer.

MEN with aggressive prostate cancer could benefit from a new drug combination that slows cancer growth, scientists say.

Prostate cancer diagnoses have risen by almost a tenth in a year. Some 58,218 men in England were diagnosed with the disease last year – up by almost 5,000 on the year before – official data has ...

Niraparib is a “maintenance” drug approved to keep certain types of cancer from coming back, including ovarian cancer, ...

An international study reports that the combination of two drugs could significantly retard the development of a dangerous ...

In men with prostate cancer, prophylactic whole pelvic radiotherapy does not improve OS compared to prostate-only dose-escalated radiotherapy.

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

Patients were more likely to have higher five-year and overall survival rates if their state had expanded Medicaid, ...

The PSA test measures the amount of a protein made by prostate gland cells and can indicate cancer. Prostate cancer blood ...

I'm a guy in my late 40s and trying to pay more attention to my health. But I'm confused about whether I should be screened ...

For patients with intermediate-risk localized prostate cancer, stereotactic body radiation therapy (SBRT) yields favorable bowel health-related quality of life (HRQOL).